BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
